Sorrento Therapeutics Inc (SRNE): Celularity has positive safety review of...

Reply Private New

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Re: None

Tuesday, 12/01/2020 8:25:53 PM

Tuesday, December 01, 2020 8:25:53 PM

Celularity has positive safety review of it's phase 1/2 trial Covid-19 drug. Sorrento has 25% interest in private Celularity .
:http://www.prnewswire.com/news-releases/celularity-announces-positive-dmc-safety-review-and-continuation-of-its-phase-iii-cynk-001-covid-19-study-301182553.html

"The refusal of the real is the number one dogma of our time" Rene Girard

Keep Last Read

Replies (1) Next 10 Prev Next

Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 09:31:06 PM
Form 8-K - Current report • Edgar (US Regulatory) • 10/27/2023 08:15:31 PM
Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2023 01:51:06 AM
Form 8-K - Current report • Edgar (US Regulatory) • 08/28/2023 09:25:07 PM
Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/07/2023 08:15:35 PM
Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2023 10:01:54 AM
Form 8-K - Current report • Edgar (US Regulatory) • 07/13/2023 10:26:26 AM